Transparency Must Include the Hard Parts.

Trust does not come from making the trial sound easier. It comes from making reality visible early enough to choose.

The hard parts belong in the first conversation.

Trial communications often lead with access, innovation, or contribution to science, then place uncertainty and burden deep in later materials. That sequence can create an expectation gap before formal consent begins. Patients deserve to see the practical and clinical reality while the decision is still open.

Transparency includes randomization, placebo or comparator conditions, invasive procedures, washout, visit frequency, travel, data collection, privacy, possible side effects, unknown benefit, alternatives, and the right to withdraw. It also includes what the team does not yet know.

Access conditions are part of the truth.

A trial may be understandable and still be infeasible. Transportation, unpaid time, childcare, caregiving, food, lodging, connectivity, language, disability access, and household cash flow can determine whether participation is possible.

Reimbursement and compensation should be explained plainly, including timing, documentation, tax considerations when relevant, and which expenses remain uncovered. Payment can remove barriers, but it should never be framed as proof that participation is the right choice.

Correct misinformation without dismissing its source.

Some concerns come from inaccurate information. Others come from historical harm, prior experience, unequal treatment, or valid uncertainty. Labeling every concern a myth can sound like the institution is defending itself instead of listening.

Begin by asking what the patient has heard and what it means to them. Acknowledge the underlying fear, correct specific inaccuracies with evidence, and preserve uncertainty where certainty does not exist. Trust grows when the answer is accurate and emotionally honest.

Transparency continues after consent.

New information, amendments, symptoms, operational changes, and accumulating burden can alter the patient's decision. Communication should explain what changed, what did not, why it matters, and what options remain available.

A transparent trial makes questions safe, answers consistent, and escalation visible. It checks understanding rather than assuming receipt. This supports activation because the patient can act from a current, realistic picture of participation, not the version they first imagined.

Sources.

1. HHS OHRP, Informed Consent FAQs
2. HHS OHRP, Key Information and Facilitating Understanding
3. HHS SACHRP, Payment to Research Subjects
4. FDA, Patient-Focused Drug Development Guidance Series

About the author

Rebecca Schelkun

Vice President, Patient Readiness

Rebecca is Vice President of Patient Readiness at Jumo Health. She combines public health expertise in epidemiology and biostatistics with experience across health equity, patient advocacy, pediatrics, rare disease, and clinical trial strategy. At Jumo, she turns protocol demands and lived experience into education, decision support, and expectation alignment patients can use.